These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28193650)

  • 21. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
    Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
    J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.
    Gervasoni C; Riva A; Cozzi V; Capetti A; Rizzardini G; Clementi E; Cattaneo D
    J Antimicrob Chemother; 2017 Jun; 72(6):1842-1844. PubMed ID: 28333266
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
    Elliot ER; Cerrone M; Challenger E; Else L; Amara A; Bisdomini E; Khoo S; Owen A; Boffito M
    J Antimicrob Chemother; 2019 Jan; 74(1):149-156. PubMed ID: 30272231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
    Burger DM; Agarwala S; Child M; Been-Tiktak A; Wang Y; Bertz R
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3336-42. PubMed ID: 17005814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Darunavir/cobicistat once daily for the treatment of HIV.
    Kakuda TN; Crauwels H; Opsomer M; Tomaka F; van de Casteele T; Vanveggel S; Iterbeke K; de Smedt G
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):691-704. PubMed ID: 25962100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacological aspects of darunavir/cobicistat].
    González-Domenech CM; Palacios R; Santos J
    Enferm Infecc Microbiol Clin; 2016 May; 34 Suppl 1():30-33. PubMed ID: 28081761
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults.
    Tashima K; Crofoot G; Tomaka FL; Kakuda TN; Brochot A; Vanveggel S; Opsomer M; Garner W; Margot N; Custodio JM; Fordyce MW; Szwarcberg J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19772. PubMed ID: 25397516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
    Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study.
    Gori A; Antinori A; Vergori A; Cossu MV; Menzaghi B; Sterrantino G; Rusconi S; Cattelan AM; Castelli F; Gianotti N; Orofino G; Ripamonti D; Savinelli S; Manzillo E; Santantonio TA; Celesia BM; Cauda R; Maserati R; d'Arminio Monforte A; Stingone C; Bonora S; Uglietti A; Termini R; Rucci F; Mancusi D
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):290-294. PubMed ID: 32101882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.
    Gallant J; Moyle G; Berenguer J; Shalit P; Cao H; Liu YP; Myers J; Rosenblatt L; Yang L; Szwarcberg J
    Curr HIV Res; 2017; 15(3):216-224. PubMed ID: 27774892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment.
    McDonald CK; Martorell C; Ramgopal M; Laplante F; Fisher M; Post FA; Liu Y; Curley J; Abram ME; Custodio J; Graham H; Rhee MS; Szwarcberg J
    HIV Clin Trials; 2014; 15(6):269-73. PubMed ID: 25433666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Darunavir concentration in PBMCs may be a better indicator of drug exposure in HIV patients.
    Nagano D; Araki T; Yanagisawa K; Ogawa Y; Gohda F; Uchiumi H; Handa H; Nakamura T; Yamamoto K
    Eur J Clin Pharmacol; 2018 Aug; 74(8):1055-1060. PubMed ID: 29721582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
    Crauwels HM; Baugh B; Van Landuyt E; Vanveggel S; Hijzen A; Opsomer M
    Clin Pharmacol Drug Dev; 2019 May; 8(4):480-491. PubMed ID: 30412360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients.
    Salerno SN; Capparelli EV; McIlleron H; Gerhart JG; Dumond JB; Kashuba ADM; Denti P; Gonzalez D
    Pharmacotherapy; 2023 Jul; 43(7):638-649. PubMed ID: 35607886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
    Moltó J; Curran A; Miranda C; Challenger E; Santos JR; Ribera E; Khoo S; Valle M; Clotet B
    J Antimicrob Chemother; 2018 Mar; 73(3):732-737. PubMed ID: 29237008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
    DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
    Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults.
    Zhang Y; Joshi S; Yazdani P; Zhan J; Wen B; Bainbridge V; Ballesteros-Perez A; Gartland M; Lataillade M
    Br J Clin Pharmacol; 2024 Jan; 90(1):274-285. PubMed ID: 37621050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interindividual and intra-individual variabilities of darunavir and ritonavir plasma trough concentrations in multidrug experienced HIV patients receiving salvage regimens.
    Baroncelli S; Villani P; Galluzzo CM; Cavalli A; Volpe A; Francisci D; Vivarelli A; Sozio F; Tedeschi S; Cirioni O; Sighinolfi L; Cusato M; Pirillo MF; Weimer LE; Fragola V; Parruti G; Regazzi M; Floridia M
    Ther Drug Monit; 2013 Dec; 35(6):785-90. PubMed ID: 24061444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
    Mathias AA; Hinkle J; Shen G; Enejosa J; Piliero PJ; Sekar V; Mack R; Tomaka F; Kearney BP
    J Acquir Immune Defic Syndr; 2008 Oct; 49(2):156-62. PubMed ID: 18769354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.